Aktie A2PUQT PHARMA EQUITY GROUP A/S
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Pharma Equity Group A/S

Aktien

A2PUQT

DK0061155009

PEG A

Markt geschlossen - Nasdaq Copenhagen
Andere Börsenplätze
 16:59:56 08.05.2024 		% 5 Tage % 1. Jan.
0,189 DKK -19,23 % Intraday Chart für Pharma Equity Group A/S -23,17 % -56,05 %
05.04. Die Tochtergesellschaft der Pharma Equity Group, Reponex Pharmaceuticals A/S, meldet sehr positive Endergebnisse der klinischen Phase-2-Studie für den patentierten Arzneimittelkandidaten RNX-051 des Unternehmens CI
20.03. Pharma Equity Group A/S meldet Ergebnis für das Geschäftsjahr zum 31. Dezember 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Exploration of options regarding a directed capital increase at market price in Pharma Equity Group A/S
Notice convening the extraordinary general meeting of Pharma Equity Group A/S
Major shareholder announcement - Pharma Equity Group A/S
Passing of the General Meeting of Pharma Equity Group A/S
The Board of Director's decision to issue convertible loans
Pharma Equity Group A/S announced that it has received DKK 7.6 million in funding
Pharma Equity A/S : Group's subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company's patented drug candidate RNX-051.
Pharma Equity Group’s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company’s patented drug candidate RNX-051.
Pharma Equity Group?s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company?s patented drug candidate RNX-051
Notice convening the annual general meeting in Pharma Equity Group A/S
Pharma Equity Group A/S (PEG) enters into an agreement with Danske Bank on the exercise of market maker in the PEG share, fund code: DK0061155009
Completion of subscription of convertible loans
Correction: Pharma Equity Group A/S - Annual Report 2023
Pharma Equity Group A/S Reports Earnings Results for the Full Year Ended December 31, 2023
Pharma Equity Group A/S Provides Group Earnings Guidance for the Full Year 2024
Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions for promoting the healing of wounds (RNX-022).
Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions for promoting the healing of wounds (RNX-022).
Completion of subscription of convertible loans
The Board of Director's decision to issue convertible loans
Pharma Equity Group A/S announced that it expects to receive DKK 7.1 million in funding
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2PUQT Aktie
  4. Nachrichten Pharma Equity Group A/S
  5. Andere Sprachen